C4 Therapeutics, Inc. cotiza a 3.06 USD y tiene una capitalización bursátil de $376M. En los últimos 12 meses ha facturado $35M con un margen de flujo de caja libre del -276.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple mye…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-0.20 | $-0.18 |
| Estimado | $-0.21 | $-0.23 | $-0.26 | $-0.39 |
| Sorpresa | — | — | +23.1% | +53.8% |
| Métrica | CCCC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -320.5% | -38.6% | -281.9% |
| Net Margin | -292.1% | -33.6% | -258.5% |
| FCF Margin | -276.2% | -13.9% | -262.4% |
| ROE | -40.9% | -40.4% | -0.5% |
| ROA | -29.2% | -32.0% | +2.8% |
| Current Ratio | 7.81 | 2.84 | +4.97 |
| Debt / Equity | — | 0.28 | — |